James A. Hendrix

12.7k total citations · 1 hit paper
55 papers, 2.2k citations indexed

About

James A. Hendrix is a scholar working on Psychiatry and Mental health, Physiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, James A. Hendrix has authored 55 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 16 papers in Physiology and 10 papers in Public Health, Environmental and Occupational Health. Recurrent topics in James A. Hendrix's work include Dementia and Cognitive Impairment Research (18 papers), Alzheimer's disease research and treatments (13 papers) and Down syndrome and intellectual disability research (8 papers). James A. Hendrix is often cited by papers focused on Dementia and Cognitive Impairment Research (18 papers), Alzheimer's disease research and treatments (13 papers) and Down syndrome and intellectual disability research (8 papers). James A. Hendrix collaborates with scholars based in United States, United Kingdom and France. James A. Hendrix's co-authors include Robert M. Williams, María C. Carrillo, Lisa J. Bain, Gil D. Rabinovici, Robert G. Thompson, John T. Hayford, Lucy Hanna, Orit H. Lesman‐Segev, Charles Apgar and Ilana F. Gareen and has published in prestigious journals such as Science, Chemical Reviews and JAMA.

In The Last Decade

James A. Hendrix

54 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

2019 369 citations Gil D. Rabinovici, Charles Apgar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James A. Hendrix United States	18	836	787	488	401	236	55	2.2k
Enrica Cavedo France	16	1.1k 1.3×	658 0.8×	622 1.3×	124 0.3×	443 1.9×	24	2.7k
Aaron Ritter United States	15	1.2k 1.5×	544 0.7×	556 1.1×	90 0.2×	329 1.4×	44	2.4k
Nathan Herrmann Canada	25	458 0.5×	779 1.0×	395 0.8×	71 0.2×	344 1.5×	62	3.2k
Samantha Rogers United Kingdom	18	799 1.0×	1.6k 2.0×	284 0.6×	169 0.4×	417 1.8×	37	3.0k
Richard D. Hartman United States	25	427 0.5×	544 0.7×	276 0.6×	170 0.4×	202 0.9×	62	1.9k
Emma L. Jones United Kingdom	7	929 1.1×	353 0.4×	604 1.2×	80 0.2×	294 1.2×	10	2.0k
Albrecht Stöffler Germany	13	1.1k 1.3×	965 1.2×	614 1.3×	84 0.2×	606 2.6×	18	3.3k
John R. Ieni United States	20	585 0.7×	930 1.2×	514 1.1×	70 0.2×	226 1.0×	35	2.3k
Alessandro Colasanti United Kingdom	27	234 0.3×	635 0.8×	496 1.0×	323 0.8×	267 1.1×	67	3.0k
Hans Jörg Möbius Germany	16	934 1.1×	911 1.2×	452 0.9×	58 0.1×	406 1.7×	22	2.7k

Countries citing papers authored by James A. Hendrix

Since Specialization

Citations

This map shows the geographic impact of James A. Hendrix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Hendrix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Hendrix more than expected).

Fields of papers citing papers by James A. Hendrix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James A. Hendrix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Hendrix. The network helps show where James A. Hendrix may publish in the future.

Co-authorship network of co-authors of James A. Hendrix

This figure shows the co-authorship network connecting the top 25 collaborators of James A. Hendrix. A scholar is included among the top collaborators of James A. Hendrix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James A. Hendrix. James A. Hendrix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schöll, Michael, Agathe Vrillon, Takeshi Ikeuchi, et al.. (2025). Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use. The Journal of Prevention of Alzheimer s Disease. 12(4). 100056–100056. 9 indexed citations

Perneczky, Robert, James A. Hendrix, Stéphane Epelbaum, et al.. (2025). How can Alzheimer's disease blood‐based biomarkers reach clinical practice?. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 17(4). e70207–e70207. 1 indexed citations

Ptomey, Lauren T., et al.. (2023). Weight management recommendations for youth with Down syndrome: Expert recommendations. Frontiers in Pediatrics. 10. 1064108–1064108. 13 indexed citations

Britton, Angela, et al.. (2023). A feasibility study demonstrating that independence, quality of life, and adaptive behavioral skills can improve in children with Down syndrome after using assistive technology. PLoS ONE. 18(5). e0284738–e0284738. 5 indexed citations

Hendrix, James A., et al.. (2023). Caregivers' concerns and supports needed to care for adults with Down syndrome. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 196(1). e32041–e32041. 7 indexed citations

Hendrix, James A., Brian Chicoine, Florence Lai, et al.. (2021). Development of a symptom menu to facilitate Goal Attainment Scaling in adults with Down syndrome-associated Alzheimer’s disease: a qualitative study to identify meaningful symptoms. Journal of Patient-Reported Outcomes. 5(1). 5–5. 4 indexed citations

Jicha, Gregory A., Erin L. Abner, Steven E. Arnold, et al.. (2021). Committee on High‐quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimer s & Dementia. 18(6). 1109–1118. 9 indexed citations

Salloway, Stephen, Kumar Budur, Ronald B. DeMattos, et al.. (2020). Advancing combination therapy for Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 6(1). e12073–e12073. 42 indexed citations

Rabinovici, Gil D., Constantine Gatsonis, Charles Apgar, et al.. (2019). Amyloid PET Leads to Frequent Changes in Management of Cognitively Impaired Patients: the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study (Plen01.001). Neurology. 92(15_supplement). 3 indexed citations

10.

Atri, Alireza, David S. Knopman, Mary S. Norman, et al.. (2018). P4‐288: DETAILS OF THE NEW ALZHEIMER'S ASSOCIATION BEST CLINICAL PRACTICE GUIDELINES FOR THE EVALUATION OF NEURODEGENERATIVE COGNITIVE BEHAVIORAL SYNDROMES, ALZHEIMER'S DISEASE AND DEMENTIAS IN THE UNITED STATES. Alzheimer s & Dementia. 14(7S_Part_30). 5 indexed citations

11.

Weıntraub, Sandra, Christopher Randolph, Lisa J. Bain, James A. Hendrix, & María C. Carrillo. (2017). Is cognitive decline measurable in preclinical Alzheimer's disease?. Alzheimer s & Dementia. 13(3). 322–323. 3 indexed citations

12.

Czaja, Sara J., Michael Gold, Lisa J. Bain, James A. Hendrix, & Marı́a C. Carrillo. (2017). Potential roles of digital technologies in clinical trials. Alzheimer s & Dementia. 13(9). 1075–1076. 3 indexed citations

13.

Lanctôt, Krista L., Joan Amatniek, Sonia Ancoli‐Israel, et al.. (2017). Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. Alzheimer s & Dementia Translational Research & Clinical Interventions. 3(3). 440–449. 251 indexed citations

14.

Holtzman, David M., María C. Carrillo, James A. Hendrix, et al.. (2016). Tau: From research to clinical development. Alzheimer s & Dementia. 12(10). 1033–1039. 109 indexed citations

15.

Liu, Enchi, Johan Luthman, Jesse M. Cedarbaum, et al.. (2015). Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). Alzheimer s & Dementia. 11(7). 840–849. 7 indexed citations

16.

Hurst, W. Jeffrey, Werngard Czechtizky, Dominique Françon, et al.. (2013). Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep–wake disorders. Bioorganic & Medicinal Chemistry Letters. 23(22). 6141–6145. 5 indexed citations

17.

Hurst, W. Jeffrey, et al.. (2013). Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3′]bipyrrolidinyl-1′-yl)phenyl]benzamide. Bioorganic & Medicinal Chemistry Letters. 23(14). 4044–4047. 4 indexed citations

18.

Hurst, W. Jeffrey, et al.. (2013). Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3′S)-2-methyl-[1,3′]bipyrrolidinyl-1′-yl)phenyl] amide as histamine H3 receptor antagonist for the treatment of depression. Bioorganic & Medicinal Chemistry Letters. 23(23). 6269–6273. 19 indexed citations

19.

Hurst, W. Jeffrey, Etienne Guillot, Werngard Czechtizky, et al.. (2013). Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part II). Bioorganic & Medicinal Chemistry Letters. 23(11). 3421–3426. 5 indexed citations

20.

Hendrix, James A., G. M. SHUTSKE, Mark Palermo, et al.. (2002). Synthesis and Structure–Activity Relationship of the Isoindolinyl Benzisoxazolpiperidines as Potent, Selective, and Orally Active Human Dopamine D4 Receptor Antagonists. ChemBioChem. 3(10). 999–1009. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact